Biocytogen and Hansoh Pharma announce an antibody license agreement
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
To create leading company developing medicines targeting metalloenzymes
The company is one of the most profitable companies manufacturing speciality chemicals in India
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
This ambitious anti-TB campaign, as part of IOCL’s CSR, aims to ensure early identification of presumptive TB and prompt diagnosis using high-sensitivity diagnostic tests at the doorstep
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
Subscribe To Our Newsletter & Stay Updated